PLUS1
1,420.60
15.60 (1.11%)
15.60 (1.11%)
Upgrade to Real-Time
Market Open
Best deals to access real time data! |
|
Real-time Level 1 for London Stock Exchange
Monthly Subscription
for only
$29.56
|
|
London Stock Exchange Level 2
Monthly Subscription
for only
$77.61
|
|
Real-time London Stock Exchange & FTSE
Monthly Subscription
for only
$88.69
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Glaxosmithkline Plc | GSK | London | Ordinary Share | GB0009252882 | ORD 25P |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 15.60 | 1.11% | 1,420.60 | 07:23:40 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1,405.00 | 1,405.00 | 1,423.20 | 1,405.00 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 1,420.20 | 1,420.60 | 0.40 | - | 5 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,681 | 1,708,009 | 1,415.62p | 24,178,837p | - | 1,284.00 - 1,847.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:23:40 | AT | 151 | 1,420.60p | GBX |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
Glaxosmithkline Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 69.42Bp | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Glaxosmithkline News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/26/2021 | 03:45 | Dow Jones News | Hikma Pharmaceuticals Says It Is in Talks With.. |
| 1/26/2021 | 03:28 | Alliance News |  TOP NEWS: Hikma In Talks To Buy Glaxo Businesses In Egypt.. |
| 1/22/2021 | 02:00 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC FDA approves ViiV Healthcare's Cabenuva.. |
| 1/22/2021 | 01:58 | Alliance News | TOP NEWS: Glaxo, Johnson & Johnson Long-Acting HIV Drug.. |
| 1/20/2021 | 11:00 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC Director/PDMR Shareholding |
| 1/20/2021 | 10:50 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC Director/PDMR Shareholding |
| 1/20/2021 | 10:02 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC Director/PDMR Shareholding |
Glaxosmithkline Discussion Forums - GSK
| Date | Time | Comments | Title |
|---|---|---|---|
| 12/15/2020 | 06:15 | - | Achiko AG: The One Ecosystem that Takes a |
| 11/15/2020 | 09:15 | - | [b]Breaking News: $GSK[/b] Investors Wish They Could Vote |
| 10/15/2020 | 10:09 | - | Decitabine has been shown to induce cancer-testis antigen |
| 10/14/2020 | 15:18 | - | SITC Decitabine gene modulation sensitizes human non–small cell lung |
| 9/12/2020 | 09:12 | - | Going forward, I would like them to transduce |
| 9/12/2020 | 09:04 | - | Lyell plan to use defined cell populations [1], |
| 9/08/2020 | 12:41 | - | Hopefully, trials testing these improvements will start early |
| 9/08/2020 | 11:29 | - | A new trial testing the NY-ESO-1 TCR-T cell |
| 8/09/2020 | 06:16 | - | Better Development Tools for a New Golden Era |
| 8/05/2020 | 18:57 | - | Calls might sky rocket tomorrow |
Historical GSK Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1,404.40 | 1,423.20 | 1,361.00 | 1,383.60 | 8,363,883 | 16.20 | 1.15% |
| 1 Month | 1,351.40 | 1,446.60 | 1,336.60 | 1,387.14 | 8,383,732 | 69.20 | 5.12% |
| 3 Months | 1,335.40 | 1,482.20 | 1,328.80 | 1,390.92 | 9,759,840 | 85.20 | 6.38% |
| 6 Months | 1,574.80 | 1,631.60 | 1,284.00 | 1,425.98 | 8,540,047 | -154.20 | -9.79% |
| 1 Year | 1,795.00 | 1,847.00 | 1,284.00 | 1,525.20 | 9,758,675 | -374.40 | -20.86% |
| 3 Years | 1,338.60 | 1,857.00 | 1,236.40 | 1,545.37 | 9,082,558 | 82.00 | 6.13% |
| 5 Years | 1,385.50 | 1,857.00 | 1,236.40 | 1,536.27 | 9,148,163 | 35.10 | 2.53% |
